Pfizer Again Tops Annual “Most Effective” Sales Force Ranking, According to Study by GfK Market Measures
Dec. 18, 2008 — For the fifth year in a row, Pfizer has claimed the top spot as the industry’s “most effective” sales force, as ranked by GfK Market Measures in a study with more than 800 physicians across 12 specialties. An analysis of the study participants’ rankings and responses to a number of related sales force issues, as viewed through the lens of GfK’s new physician attitudinal promotional segmentation, Segment Tracker™, reveals key differences across physician groups in their perceptions of sales representative interactions.more >>
Managed Markets Monitor Provides Industry’s First Continuous Audit of Sales and Marketing Activities Targeted at Managed Care Decision Makers
Dec. 4, 2008 — GfK Market Measures announced today an exclusive new tool for pharmaceutical manufacturers to assess the value and impact of their increasingly important managed markets sales and marketing activities. Managed Markets Monitor provides the industry’s first-ever continuous audit and tracking of sales force interactions, through quarterly reporting from a panel of 40 managed care decision makers who are collectively responsible for almost half of all commercially covered lives.more >>
Atypical Antipsychotic Drugs Primed for Significant Growth in Antidepressant Market, According to Study by GfK Market Measures
Dec. 3, 2008 — Abilify, one of the first atypical antipsychotics to receive an indication as an add-on therapy for the treatment of depression, has garnered the attention of physicians since its FDA approval in November 2007. But real growth for this brand – and other market entrants such as Seroquel, which is expected to receive a similar indication in 2009 – will require greater comfort among primary care physicians (PCPs) in using atypical antipsychotics with a broader set of depression sufferers, according to new research by GfK Market Measures.more >>
Osteoporosis Drugs That Differentiate Based on Concomitant Indications and Less Frequent Dosing See Most Market Gains, According to Study by GfK Market Measures
Nov. 5, 2008 — A look at the key drivers of prescribing among physicians treating patients with osteoporosis reveals that drugs such as Evista, with its concomitant indication for post-menopausal women at risk for breast cancer, and just-launched yearly Reclast, which boasts the convenience of less-frequent dosing, are the brands expected to lead the market, according to new research by GfK Market Measures.more >>
Published Article: Sales Force Report 2008
November 1, 2008 - Medical Marketing & Media -"Sales Force Report 2008." Which pharma company earned the coveted spot for having the most effective sales force this year? How do current rankings compare with last year? These questions are answered as part of the cover story on pharmaceutical sales forces in Medical Marketing & Media’s November issue, where GfK Market Measures reveals the results of its industry benchmark 2008 sales force effectiveness study.more >>